Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.22.2.2
Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Jun. 21, 2022
Jan. 01, 2022
Jul. 22, 2016
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
May 24, 2021
Dec. 04, 2020
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common stock, shares authorized       200,000,000   200,000,000   150,000,000      
Common stock par value (in dollars per share)       $ 0.0001   $ 0.0001   $ 0.0001      
Preferred stock, shares authorized       2,000,000   2,000,000   2,000,000      
Preferred stock, shares issued       250,000   250,000   250,000      
Aggregate value of shares subscribed       $ 4   $ 4   $ 4,329      
Common stock, shares issued       106,427,767   106,427,767   93,582,991      
Common stock, shares issuable       6,987   6,987   2,536,607      
Shares available for future sale       413,990   413,990          
Increase in number of shares of common stock authorized 50,000,000                    
Fortress Biotech, Inc [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Issuance of common shares - Founders Agreement (in shares)   2,536,607       1,196,187          
Percentage of fully diluted equity   2.50% 2.50%     2.50%          
Expenses from related party transaction       $ 200 $ 100 $ 800 $ 400        
Issuance of common shares (in shares)           241,260 517,304        
Shares issued, price per share       $ 1.16 $ 3.84 $ 1.16 $ 3.84        
Common stock, shares issuable       6,987   6,987          
Proceeds from issuance of common shares           $ 6,600          
At the Market Offering [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Agent commission (as a percent)                     3.00%
Issuance of common shares (in shares)           7,900,000 17,300,000        
Shares issued, price per share       $ 0.84 $ 3.87 $ 0.84 $ 3.87        
Proceeds from issuance of common shares           $ 6,600 $ 66,900        
Aggregate fees of stock issuance           100 1,300        
Registration Statements [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Sale of Stock aggregate offering price - Founders Agreement                 $ 200,000 $ 100,000  
Shares available for future issuance - Founders Agreement       $ 8,000   $ 8,000          
Class A Common Shares [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common stock, shares issued       845,385   845,385   845,385      
General and administrative [Member] | Fortress Biotech, Inc [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Expenses from related party transaction       $ 18 $ 100 $ 900 $ 1,700